|
|
EQSNews: Heidelberg Pharma AG
/ Key words: Quarterly / Interim Statement
Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024
25.04.2024 / 07:21 CET/CEST
The issuer is solely responsible for the content of this announcement.
Heidelberg Pharma AG: Interim Management S... Lire le communiqué |
|
| |
|
| |
|
|
EQSNews: Heidelberg Pharma AG
/ Key words: Miscellaneous
Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
05.04.2024 / 09:30 CET/CEST
The issuer is solely responsible for the content of this announcement.
PRESS RELEASE
Heidelberg Pharma to host R&... Lire le communiqué |
|
| |
|
| |
|
|
EQSNews: Heidelberg Pharma AG
/ Key words: Miscellaneous
Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP101
27.03.2024 / 09:01 CET/CEST
The issuer is solely responsible for the content of this announcement.
PRESS RELEASE
Heidelberg... Lire le communiqué |
|
| |
|
| |
|
|
EQSNews: Heidelberg Pharma AG
/ Key words: Annual Results
Heidelberg Pharma announces financial figures and reports on successful business performance in 2023
25.03.2024 / 07:10 CET/CEST
The issuer is solely responsible for the content of this announcement.
PRESS RELEASE
Heidelberg... Lire le communiqué |
|
| |
|
| |
|
|
EQSNews: Heidelberg Pharma AG
/ Key words: Financing
Heidelberg Pharma announces receipt of nonrefundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty
19.03.2024 / 09:47 CET/CEST
The issuer is solely responsible for the content of this announcement.... Lire le communiqué |
|
| |
|
| |
|
|
EQSNews: Heidelberg Pharma AG
/ Key words: Study
Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP101 in Phase I/IIa multiple myeloma study
18.03.2024 / 07:25 CET/CEST
The issuer is solely responsible for the content of this announcement.
PRESS RELEASE... Lire le communiqué |
|
| |
|
| |
|
|
OriginalResearch: Heidelberg Pharma AG von EQUITS GmbH
Einstufung von EQUITS GmbH zu Heidelberg Pharma AG
Unternehmen: Heidelberg Pharma AG
ISIN: DE000A11QVV0
Anlass der Studie: Research Update
Empfehlung: Kaufen
seit: 07.03.2024
Kursziel: 8,90
Kursziel auf Sicht von: 12 Monate
Letzte Ratingänderung:
Analyst: Thomas Schiessle
EQUI.TS GmbH 07.03.2024 bekr... Lire le communiqué |
|
| |
|
| |
